Loading clinical trials...

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases | Clinical Trials | Clareo Health

COMPLETED

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Dynamic ctDNA Detection for Guiding Adjuvant Therapy and Recurrence Monitoring After Curative Resection of Colorectal Cancer Liver Metastases: A Prospective Study

NCT06404593•Peking University Cancer Hospital & Institute

View on ClinicalTrials.gov

Summary

Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

Eligibility

Age

20 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Before implementing any trial-related procedures, written informed consent should be signed;
•2. \>=20 and \<= 85 years old, male or female;
•3. Patients with liver metastases pathologically confirmed as colorectal adenocarcinoma;
•4. According to the Response Evaluation Criteria for Solid Tumors (RECIST version 1.1), there is at least one lesion that can be measured by imaging;
•5. The multidisciplinary team (MDT) confirmed that the liver metastases were initially resectable ,without locally treatable extrahepatic metastases;
•6. The general physical condition is good (ECOG score 0-1);
•7. Life expectancy of more than 3 months;
•8. There is no obvious symptoms of primary bleeding, obstruction and other indications for emergency surgery;
•9. adequate organ function;
•10. samples meet NGS quality control requirements;
+1 more criteria

Exclusion Criteria

•1. Patients who are intolerant to systemic chemotherapy or surgery;
•2. Patients with multiple primary lesions;
•3. Blood samples and/or baseline tissue samples that do not meet the requirements for testing (hemolysis, low tumor cell content, insufficient DNA extraction yield, etc.);
•4. Excessive tissue necrosis after conversion therapy, making it impossible to sample according to testing requirements
•5. Patients who have not undergone surgery after conversion therapy, only receiving radiofrequency ablation or chemotherapy follow-up
•6. Not all metastatic lesions were resected after conversion therapy, or liver metastatic lesions did not achieve R0 resection
•7. No definite mutations detected in the tissue, or mutations detected in tumor tissue were not covered by the designed small panel.

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

June 18, 2019

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

May 8, 2024

Enrollment

270

ACTUAL participants

Conditions

Liver MetastasesColorectal CancerSurgeryCirculating Tumor DNAMinimal Residual Disease

Interventions

Blood sampling

DIAGNOSTIC_TEST

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

RECRUITING

Evaluation of Resection Techniques for Pancreatic Tumors

NCT05128890

SurgeryLiver Tumor+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Inclusion Criteria

Exclusion Criteria

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Evaluation of Resection Techniques for Pancreatic Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

EOIFP Block Versus OSTAP Block for Upper Abdominal Surgery

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors